Drug intelligence / Profile preview

Haimo Hemostatic Capsules

Development stage: Unknown
Lead developer: Hebei Wanbang Fu Lin Pharmaceutical
Administration: Oral

Overview

Haimo Hemostatic Capsules (海墨止血胶囊) is an approved traditional Chinese medicine (TCM) formulation developed and manufactured by Hebei Wanbang Fu Lin Pharmaceutical. Administered orally as a capsule, the drug is indicated for bleeding and hemostasis according to traditional Chinese medicine principles. As is common with traditional herbal formulations, the manufacturer has not specified a single molecular mechanism of action; instead, its therapeutic effects are attributed to the synergistic properties of its constituent herbal ingredients. It is part of the company's portfolio of marketed TCM products in China.

Brand names: Haimo Hemostatic Capsules
Other names: 海墨止血胶囊

Beyond the preview

Go deeper on Haimo Hemostatic Capsules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Haimo Hemostatic Capsules.

Explore the full profile